BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
07/12/2021
Initial Lawsuit
07/12/2021
Lawsuit Progression
01/04/2022
Settlement
11/07/2022
Investigation regarding statements made by Kanzhun in connection with a cybersecurity review in China.
07/05/2021
Kanzhun discloses that it is subject to a cybersecurity review by the Cyberspace Administration of China, following an announcement on their website.
“During the review period, “BOSS Zhipin” app is required to suspend new user registration in China to facilitate the process. The Company will fully cooperate with the PRC government authority during the review process. The Company plans to conduct a comprehensive examination of cybersecurity risks and continue to enhance its cybersecurity awareness and technology capabilities.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$30.52 | $36.31 | $-5.79 | -15.95% |
This is a class action on behalf of persons or entities who purchased or otherwise acquired publicly traded Kanzhun securities between June 11, 2021 and July 2, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(1) Kanzhun would face an imminent cybersecurity review by the CAC;
(2) the CAC would require Kanzhun to suspend new user registration on its BOSS Zhipin app;
(3) Kanzhun needed to “to conduct a comprehensive examination of cybersecurity risks”;
(4) Kanzhun needed to “enhance its cybersecurity awareness and technology capabilities”;
(5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
01/04/2022
The court issued an order appointing the lead plaintiff and lead counsel.
03/04/2022
This is a class action on behalf of persons or entities who purchased publicly traded Kanzhun American Depository Shares (ADSs) between June 11, 2021 and July 2, 2021, inclusive.
Operative complaint
05/03/2022
A motion to dismiss was filed with the court.
On 11/07/2022, lead counsel The Rosen Law Firm, P.A. announced a proposed class action settlement.
The court preliminarily approved the settlement on 11/10/2022. The settlement has a total value of $2,250,000 in Cash.
The notice states that you may be included, if you purchased or otherwise acquired the company’s publicly traded common stock during the period from 06/11/2021 to 07/02/2021, inclusive.
According to the notice, the estimated average cash recovery per damaged share of common stock will be approximately $N/A per share, before deduction of court-approved fees and expenses. Lead Counsel filed a motion for an award of attorneys’ fees not to exceed 33% of the $2,250,000 and payment of expenses not to exceed $45,000.
For information purposes only, last updated on 11/19/2022. Contact the claims administrator or lead counsel for further information.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.